Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

Slides:

Advertisements

Similar presentations

Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles Ryan G. Steward,

Advertisements

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Demián Glujovsky, M.D., M.Sc., Cynthia Farquhar, M.D., M.P.H.

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome.

Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger? Matthew.

Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment Javier Domingo, M.D., Vicente.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates Liang Zhou, M.D., Rong Li, M.D., Ph.D., Rong.

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase Michael von Wolff, M.D., Christian J. Thaler,

Mike Ripley, M. D. , F. R. C. S. C. , Andrea Lanes, M. Sc

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Evaluation of the immature human oocytes from unstimulated cycles in polycystic ovary syndrome patients using a novel scoring system Shan Liu, M.D.,

Live birth of twins derived from zona-free oocytes

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Selection of patients for natural cycle in vitro fertilization combined with in vitro maturation of immature oocytes Jin-Ho Lim, M.D., Seong-Ho Yang,

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Oocyte cryopreservation

Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials Valeria M.S.

Robert F. Casper, M.D. Fertility and Sterility

Xiuye Xing, M. D. , Ph. D. , Han Zhao, M. D. , Ph. D. , Mei Li, M. Sc

A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization Laura Detti, M.D., Daniel B. Williams, M.D., Jared.

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis Laura P. Smith, M.D.,

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

Does stimulation with human gonadotropins and gonadotropin-releasing hormone agonist enhance and accelerate the developmental capacity of oocytes in human.

How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis Dimitra Kyrou,

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Retrieval of immature oocytes after chemotherapy for Hodgkin's disease and prolonged ovarian down-regulation with gonadotropin-releasing hormone agonist

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Eva Balkenende, Taghride Dahhan, M. D. , Fulco van der Veen, M. D, Ph

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,

Prospective cohort study of three- versus two-dimensional ultrasound for prediction of oocyte maturity Doron Shmorgun, M.D., Edward Hughes, M.D., Patrick.

David E. Reichman, M. D. , Stacey A. Missmer, Sc. D. , Katharine F

Ri-Cheng Chian, Ph.D., Peter S. Uzelac, M.D., Geeta Nargund, M.D.

Progesterone level at oocyte retrieval predicts in vitro fertilization success in a short- antagonist protocol: a prospective cohort study Shweta Nayak,

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Lindsay M. Mains, M. D. , Babak Vakili, M. D. , Yves Lacassie, M. D

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Sedigheh Borna, M.D., Azita Nasery, M.D. Fertility and Sterility

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis Ernesto Bosch, M.D., Elena.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

A woman with premature ovarian failure induced by Tripterygium wilfordii Hook.f. gives birth to a healthy child Xin Chen, M.D., M.Sc., Shi-ling Chen,

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study Ahmed Badawy, M.D., Aboubakr.

Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian.

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:

Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment Daniel Bodri, M.D., M.Sc.,

Presentation transcript:

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study Georg Griesinger, M.D., M.Sc., Ph.D., Laura Schultz, Thomas Bauer, M.D., Anke Broessner, M.D., Thorsten Frambach, M.D., Stefan Kissler, M.D., Ph.D. Fertility and Sterility Volume 95, Issue 6, Pages 2029-2033.e1 (May 2011) DOI: 10.1016/j.fertnstert.2011.01.163 Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Cumulative rate of live birth per patient stratified for the number of oocytes retrieved after GnRH agonist triggering. Fertility and Sterility 2011 95, 2029-2033.e1DOI: (10.1016/j.fertnstert.2011.01.163) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Cumulative rate of a positive hCG test leading to a live birth. Fertility and Sterility 2011 95, 2029-2033.e1DOI: (10.1016/j.fertnstert.2011.01.163) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions